Targeted research accelerates development and improves results
At Novartis Oncology, research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and knowledge of disease pathways. Our targeted research strategy leverages biomarkers and targeted drug development focused on individual patients.
Our approach speeds the availability of targeted treatments through:
- Enhanced screening and identification of promising compounds and combinations.
- Better patient selection and response prediction biomarkers to increase likelihood of success.
- Delivery of targeted treatments with companion diagnostics to optimize patient outcomes.
Thanks to this approach, the Novartis Oncology Pipeline is one of the strongest and most productive pipelines in the industry.